Compare like-for-like revenue
The reported-period revenue series records CAD 0 for the period ended June 30, 2026.
—
—
—
Cardiol Therapeutics
—
—
Live Price
CIN RESEARCH · DATED EVIDENCE
Dated financial evidenceCardiol Therapeutics: review the dated company evidence.
The reported-period revenue series records CAD 0 for the period ended June 30, 2026. Cash and operating cash flow are available on a matching dated basis.
Latest financial observation 2026-06-30Last reported price 2026-11-06Research checked 2026-11-06 13:30 UTC
The check time records a research refresh. Each financial figure and price keeps its own reporting date.
Put cash beside operating cash flow
Period-end cash was CAD 26.09m at 2026-06-30. The matching reported-period operating cash outflow was CAD 4.38m. Later financing and cash movements are not established by this snapshot.
Follow the primary disclosures
The available record includes 3 primary disclosures. The latest is 2026-07-09. This is the available feed record, not a claim of complete filing coverage.
Reported financial evidence
| Measure | Reported value & unit | Period & interval | Evidence basis |
|---|---|---|---|
| Revenue | CAD 0Unit: CAD | Quarterly series | Dated financial series |
| Cost of revenue | CAD 26,777Unit: CAD | Quarterly series | Dated financial series |
| Gross profit | CAD -26,777Unit: CAD | Quarterly series | Dated financial series |
| Operating income | CAD -11.28mUnit: CAD | Quarterly series | Dated financial series |
| EBITDA | CAD -8.92mUnit: CAD | Quarterly series | Dated financial series |
| Cash balance | CAD 26.09mUnit: CAD | Balance at period end | Dated financial series |
| Total assets | CAD 29.37mUnit: CAD | Balance at period end | Dated financial series |
| Total liabilities | CAD 5.33mUnit: CAD | Balance at period end | Dated financial series |
| Shareholders’ equity | CAD 24.04mUnit: CAD | Balance at period end | Dated financial series |
| Operating cash flow | CAD -4.38mUnit: CAD | Quarterly series | Dated financial series |
| Free cash flow | CAD -4.38mUnit: CAD | Quarterly series | Dated financial series |
A balance at period end is not income over a period. “Quarterly series” follows the available classification; the source disclosure establishes the actual reporting interval.
What changed against the prior year
Only the same measure, unit, reporting frequency and prior-year period end are compared. A reported change is not an investment rating.
Unchanged
- 2025-06-30
- CAD 0
- 2026-06-30
- CAD 0
Decreased
- 2025-06-30
- CAD -7,676,158
- 2026-06-30
- CAD -11,280,341
Decreased
- 2025-06-30
- CAD -8,328,901
- 2026-06-30
- CAD -8,916,790
Increased +43.4%
- 2025-06-30
- CAD 18,195,052
- 2026-06-30
- CAD 26,092,365
Increased +47.3%
- 2025-06-30
- CAD 19,937,699
- 2026-06-30
- CAD 29,370,566
Decreased -34.4%
- 2025-06-30
- CAD 8,129,824
- 2026-06-30
- CAD 5,331,233
Increased +103.6%
- 2025-06-30
- CAD 11,807,875
- 2026-06-30
- CAD 24,039,331
Increased
- 2025-06-30
- CAD -4,550,574
- 2026-06-30
- CAD -4,381,076
Increased
- 2025-06-30
- CAD -4,557,013
- 2026-06-30
- CAD -4,384,107
What to investigate next
- Resolve the conflicting financial observations against the primary report.
- Read the latest linked company disclosures and any reporting after the financial period.
- Check post-period financing, share issuance and changes in cash before drawing a current valuation conclusion.
Evidence boundaries
- Conflicting observations for the same concept, period and reporting basis are withheld.
- Interim frequency is provider-classified. Generic form labels are not treated as proof of an SEC filing or a three-month reporting duration.
- The earlier rating is not presented as a current conclusion. This report is rebuilt from dated evidence.
Primary company disclosures
Independent evidence summary. No broker consensus, price target or investment rating is manufactured. Research standards →
Price History · CAD
5 Years
Fundamentals
SEC & Market Data
Loading fundamentals…
Analyst Consensus
Loading analyst data…
Valuation Multiples
Loading…
Price Statistics
Loading…
Financing Activity
Loading financing data…
Insider Transactions
Loading insider data…
Regulatory Filings
Loading regulator disclosures…
Peer Comparison
Loading peer data…
CONTINUE YOUR RESEARCH